

before the meeting about the actual time allotted per speaker.

If possible, oral public commenters should send a copy of their slides and/or statement or talking points to *NTP-Meetings@icf.com* by June 1, 2021.

**Meeting Materials:** The preliminary meeting agenda is available on the meeting web page (<https://ntp.niehs.nih.gov/go/165>) and will be updated one week before the meeting. Individuals are encouraged to access the meeting web page to stay abreast of the most current information regarding the meeting.

**Background Information on the BSC:** The BSC is a technical advisory body comprised of scientists from the public and private sectors that provides primary scientific oversight to the NTP. Specifically, the BSC advises the NTP on matters of scientific program content, both present and future, and conducts periodic review of the program for the purpose of determining and advising on the scientific merit of its activities and their overall scientific quality. Its members are selected from recognized authorities knowledgeable in fields such as toxicology, pharmacology, pathology, epidemiology, risk assessment, carcinogenesis, mutagenesis, cellular biology, computational toxicology, neurotoxicology, genetic toxicology, reproductive toxicology or teratology, and biostatistics. Members serve overlapping terms of up to four years. The BSC usually meets periodically. The authority for the BSC is provided by 42 U.S.C. 217a, section 222 of the Public Health Service Act (PHS), as amended.

The BSC is governed by the provisions of the Federal Advisory Committee Act, as amended (5 U.S.C. app.), which sets forth standards for the formation and use of advisory committees.

Dated: April 15, 2021.

**Brian R. Berridge,**  
*Associate Director, National Toxicology Program.*

[FR Doc. 2021-09331 Filed 5-3-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; PAR20-072, NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

**Date:** May 27, 2021.

**Time:** 10:00 a.m. to 1:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G45, Rockville, MD 20892 (Virtual Meeting).

**Contact Person:** Vanitha Sundaresa Raman, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G45, Rockville, MD 20852, 301-761-7949, [vanitha.raman@nih.gov](mailto:vanitha.raman@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 28, 2021.

**Tyeshia M. Roberson,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-09268 Filed 5-3-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Natural Product Based Nanoparticles as Dietary Management and/or Treatment of Inflammatory Related Diseases

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information

section of this notice to MaDu, LLC located at 2025 Broadway, Suite 23E, New York, NY 10023.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before May 19, 2021 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Michelle A. Favila, Ph.D., Technology Transfer Manager, National Institutes of Health, NCI Technology Transfer Center by email ([michelle.favila@nih.gov](mailto:michelle.favila@nih.gov)).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

*HHS Ref No. E-154-2018-0: Binary Lipid Bilayer-Containing Vesicles Comprising Embedded Cytotoxic Agents and Methods of Making and Using the Same*

1. United States Provisional Patent Application No. No. 62/697,287 filed July 12, 2018. [HHS Ref No. E-154-2018-0-US-01]

2. International Patent Application No. PCT/US2019/041464 filed July 11, 2019. [HHS Ref. No. E-154-2018-0-PCT-02]

3. Canadian Patent Application No. 3106008 filed July 11, 2019. [HHS Ref No. E-154-2018-0-CA-03]

4. European Patent Application 19746275.7 filed July 11, 2019. [HHS Ref No. E-154-2018-0-EP-04]

5. Japanese Patent Application 2021-500734 filed July 11, 2019. [HHS Ref No. E-154-2018-0-JP-05] and

6. United States Patent Application 17/259,499 filed January 11, 2021 [HHS Ref No. E-154-2018-0-US-01]

The patent and patent application rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and will be less than the full patent term and the field of use may be limited to the following: Development and commercialization of the Binary Lipid Nanoparticle encapsulating known natural products curcumin, vitamin D, and/or L-serine that are Generally Recognized as Safe for use as medical foods, as defined by the FDA, or over-the-counter products for the management of pain and inflammatory-related diseases. The prospective licensee plans to develop Medical Foods, which is defined by the FDA as

“food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”

This technology discloses formulation and methods of using novel stealth lipid nanoparticles that have a high stability and payload capacity. Combination of these nanoparticles with selected agents may have various medical applications for cancer and anti-inflammatory indications.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 16, 2021.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2021-09332 Filed 5-3-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed).

*Date:* May 26, 2021.

*Time:* 10:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Tara Capece, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20852, 240-191-4281, [capecet2@niaid.nih.gov](mailto:capecet2@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 28, 2021.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-09270 Filed 5-3-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Athenex, Inc. (“Athenex”) headquartered in Buffalo, NY.

**DATES:** Only written comments and/or applications for a license which are

received by the National Cancer Institute’s Technology Transfer Center on or before May 19, 2021 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240) 276-5530; Email: [suna.gulay@nih.gov](mailto:suna.gulay@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

##### Group A

*E-237-2017-0/2: T Cell Receptors Recognizing Mutated P53*

1. US Provisional Patent Application 62/565,383, filed September 29, 2017 (E-237-2017-0-US-01);
2. International Patent Application PCT/US2018/051285, filed September 17, 2018 (E-237-2017-2-PCT-01);
3. Australian Patent Application 2018342246, filed September 17, 2018 (E-237-2017-2-AU-02);
4. Brazilian Patent Application BR112020006012-7, filed September 17, 2018 (E-237-2017-2-BR-03);
5. Canadian Patent Application 3077024, filed September 17, 2018 (E-237-2017-2-CA-04);
6. Chinese Patent Application 201880074539.8, filed September 17, 2018 (E-237-2017-2-CN-05);
7. Costa Rica Patent Application 2020-0170, filed September 17, 2018 (E-237-2017-2-CR-06);
8. Eurasian Patent Application 202090757, filed September 17, 2018 (E-237-2017-2-EA-07);
9. European Patent Application 18780006.5, filed September 17, 2018 (E-237-2017-2-EP-08);
10. Israeli Patent Application 273515, filed September 17, 2018 (E-237-2017-2-IL-09);
11. India Patent Application 202047013911, filed September 17, 2018 (E-237-2017-2-IN-10);
12. Japanese Patent Application 2020-517556, filed September 17, 2018 (E-237-2017-2-JP-11);
13. Korean Patent Application 2020-7012344, filed September 17, 2018 (E-237-2017-2-KR-12);
14. Mexico Patent Application MX/a/2020/003504, filed September 17, 2018 (E-237-2017-2-MX-13);
15. New Zealand Patent Application 763023, filed September 17, 2018 (E-237-2017-2-NZ-14);
16. Singapore Patent Application 11202002636P, filed September 17, 2018 (E-237-2017-2-SG-15);